Assessment of the Short-Term Safety and Tolerability of a Quantified 80 % Ethanol Extract from the Stem Bark of Nauclea pobeguinii (PR 259 CT1) in Healthy Volunteers: A Clinical Phase I Study

Abstract

The aim of this study was to evaluate the short-term safety and tolerability of an antimalarial herbal medicinal product (PR 259 CT1) consisting of a quantified 80 % ethanol extract from the stem bark of Nauclea pobeguinii when given orally to healthy adult male volunteers. The amount of the major alkaloid strictosamide in the extract was determined by a validated HPLC method and was shown to be 5.6 %. The herbal preparation was formulated in a gelatine capsule form containing 500 mg of PCR 259 CT1. A sample of 15 healthy male volunteers, selected using the Lot Quality Assurance of Sampling (LQAS) method, was eligible for inclusion after fulfilment of the inclusion criteria and clinical examination by a physician. The volunteers were treated in an outpatient clinic with a drug regimen of two 500 mg capsules three times daily (each eight hours) for seven days, during meals. Safety and tolerability were monitored clinically, haematologically, biochemically and by electrocardiographic (ECG) examination at days 0, 1, 3, 7 and 14. Adverse effects were recorded by self-reporting of the participants or by detection of abnormalities in clinical examinations by a physician. The oral administration of PR 259 CT1 at high doses of 2 × 500 mg/capsule/day for 7 days was found to induce no significant changes in the concentration levels of all investigated haematological, biochemical, electrocardiogram and vital sign parameters and physical characteristics after 14 days of treatment compared to those seen in the baseline data. The concentration levels of all evaluated parameters were within the normal limits as reported in the literature. All adverse events noted were mild and self-resolving including increase of appetite (33 %), headache (20 %) and nausea (20 %). Other minor side effects were insomnia, somnolence and asthenia (7 %). Thus, PR 259 CT1 presented a significant safety and tolerability in healthy volunteers to allow its further development by starting a phase II clinical trial.

Key words

Nauclea pobeguinii - Rubiaceae - quantified extract - strictosamide - phase I clinical study

References

• 1 American Cancer Society .Clinical trials: what you need to know. Available at. http://www.cancer.org/docroot/ETO Last accessed March 17, 2010
• 2 US Department of Health and Human Services .Guidance for industry, investigators, and reviewers – exploratory IND studies. Geneva; WHO 2006 http://www.fda.gov/downloads/Drugs/Guidance%20ComplianceRegulatoryInformation/Guidances/ucm078933.pdf Last accessed March 17, 2010
• 3 WHO .General guidelines for methodologies on research and evaluation of traditional medicine. Geneva; WHO 2000 http://whqlibdoc.who.int/hq/2000/WHO_EDM_TRM_2000.1.pdf Last accessed March 17, 2010
• 4 Willcox M, Olanrewaju O. Guidelines for clinical studies on herbal antimalarials. Willcox M, Bodeker G, Rasoanaivo P Traditional medicinal plants and malaria. Boca Raton, FL; CRC Press 2004: 321-332
• 5 Mesia K G, Tona L G, Penge O, Lusakibanza M, Nanga T M, Cimanga K R, Apers S, Van Miert S, Totté J, Pieters L, Vlietinck A J. Antimalarial activities and toxicities of three plants used as traditional remedies for malaria in the Democratic Republic of Congo: Croton mubango, Nauclea pobeguinii and Pyrecanntha staudtii.  Ann Trop Med Parasitol. 2005;  99 345-357
• 6 Dhooghe L, Mesia K, Kohtala E, Tona L, Pieters L, Vlietinck A J. Development and validation of an HPLC-method for the determination of alkaloids in the stem bark extract of Nauclea pobeguinii.  Talanta. 2008;  15 462-468
• 7 McGee J D, Isaacson P G, Wright N A. Oxford textbook of pathology, Vol. 2b. Oxford; Oxford University Press 1992: 1707
• 8 Chapelon-Abric C. Eletrocardiogramme normal de l'adulte.  EMC – Cardiologie-Angéiologie. 2004;  1 2-10
• 9 Talley N, O'Connor S. Clinical examination, 5th edition. Sydney; Churchill Livingstone 2006
• 10 WHO .Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Adapted from “The use of essential drugs; 8th list”. WHO technical report series, No. 850. Geneva; WHO 1995
• 11 Karbwang J, Patou C. Standard operating procedures for clinical investigators. TDR/TDP/SOP/99.1.version 1.1. Geneva; WHO 1999 http://whqlibdoc.who.int/hq/1999/TDR_TDP_SOP_99.1.pdf Last accessed May 10, 2010
• 12 Lemeshow S, Taber S. Lot quality assurance sampling: single- and double-sampling plans.  World Health Stat Q. 1991;  44 115-132
• 13 Council for International Organizations of Medical Sciences (CIOMS) .International ethical guidelines for biomedical research involving human subjects. Geneva; CIOMS 2002 http://whqlibdoc.who.int/emro/2004/9290213639_annex2.pdf Last accessed May 10, 2010
• 14 World Medical Association (WMA) .Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html Last accessed May 10, 2010
• 15 Moreno A, Badell E, Van Rooijen N, Druilhe P. Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies.  Antimicrob Agents Chemother. 2001;  45 1847-1853
• 16 Mesia K G, Cimanga K R, Dhooghe L, Cos P, Apers S, Totté J, Tona L G, Pieters L, Vlietinck A J, Maes L. Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract.  J Ethnopharmacol. ;  , in press
  
• 17 Fernex M. Clinical trials – phases I and II. Peters W, Richards WHG Antimalarial drugs I. Berlin; Springer Verlag 1984
• 18 DMID .NIH division of microbiology and infectious diseases adult toxicity table, May 2001. http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%2520final.pdf Last accessed 11 May 2010
• 19 WHO .Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003. Volume 50. Geneva; WHO 2003: 1-68
• 20 WHO .World Health Organisation traditional medicine strategy 2002 – 2005. Geneva; WHO 2002
• 21 Willcox M, Bodeker G. Traditional herbal medicines for malaria.  Br Med J. 2004;  329 1156-1159
• 22 Modi A A, Wright E C, Seeff L B. Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review.  Antiviral Ther. 2007;  12 285-295
• 23 Snow R W, Molyneux C S, Njeru E K, Omumbo J, Nevill C G, Muniu E, Marsh K. The effects of malaria control on nutritional status in infancy.  Acta Trop. 1997;  65 1-10
• 24 Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.  J Electrocardiol. 2004;  37 25-29